Pharmabiz
 

Biolin Scientific, Nanion Technologies enter licensing agreement

StockholmSaturday, February 7, 2015, 17:00 Hrs  [IST]

Biolin Scientific Holding AB, a leading Nordic instrumentation company, and Nanion Technologies GmbH, Germany have entered into a licensing agreement. Biolin Scientific has agreed to grant a non-exclusive license for the key patent related to performing multi-hole, high-throughput ion channel screening to Nanion Technologies in exchange for an undisclosed license fee. The non-exclusive license will provide Nanion Technologies with freedom to operate for the entire life time of the patents.

The patent describes a method for ensuring high quality data by analyzing multiple cells and thus multiple sets of ion channels under one experimental condition, thus providing extremely high quality data and a truly high-throughput screening method.

Johan von Heijne, president and CEO of Biolin Scientific states, “This deal affirms our commitment to invest in high-throughput screening using automated patch clamping, and our intent to vigorously protect our broad range of innovations and intellectual property rights. We are committed to our full range of brands including Sophion, Q-Sense, Attension and KSV NIMA branded products”.

Niels Fertig, CEO of Nanion Technologies comments, “The license agreement is fully in-line with our long-term strategy to safeguard our ability to continue to develop new and exciting products in the field of automated patch clamping”.

Nanion Technologies was founded in 2002 as a spin-off from the University of Munich, Center for Nanoscience (CeNS). Over the last 13 years it has grown to a strong company with over 80 employees worldwide.

 
[Close]